Literature DB >> 25778676

Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases.

Bernhard F Becker1, Matthias Jacob2, Stephanie Leipert1, Andrew H J Salmon3, Daniel Chappell4.   

Abstract

The endothelial glycocalyx has a profound influence at the vascular wall on the transmission of shear stress, on the maintenance of a selective permeability barrier and a low hydraulic conductivity, and on attenuating firm adhesion of blood leukocytes and platelets. Major constituents of the glycocalyx, including syndecans, heparan sulphates and hyaluronan, are shed from the endothelial surface under various acute and chronic clinical conditions, the best characterized being ischaemia and hypoxia, sepsis and inflammation, atherosclerosis, diabetes, renal disease and haemorrhagic viral infections. Damage has also been detected by in vivo microscopic techniques. Matrix metalloproteases may shed syndecans and heparanase, released from activated mast cells, cleaves heparan sulphates from core proteins. According to new data, not only hyaluronidase but also the serine proteases thrombin, elastase, proteinase 3 and plasminogen, as well as cathepsin B lead to loss of hyaluronan from the endothelial surface layer, suggesting a wide array of potentially destructive conditions. Appropriately, pharmacological agents such as inhibitors of inflammation, antithrombin and inhibitors of metalloproteases display potential to attenuate shedding of the glycocalyx in various experimental models. Also, plasma components, especially albumin, stabilize the glycocalyx and contribute to the endothelial surface layer. Though symptoms of the above listed diseases and conditions correlate with sequelae expected from disturbance of the endothelial glycocalyx (oedema, inflammation, leukocyte and platelet adhesion, low reflow), therapeutic studies to prove a causal connection have yet to be designed. With respect to studies on humans, some clinical evidence exists for benefits from application of sulodexide, a preparation delivering precursors of the glycocalyx constituent heparan sulphate. At present, the simplest option for protecting the glycocalyx seems to be to ensure an adequate level of albumin. However, also in this case, definite proof of causality needs to be delivered.
© 2015 The British Pharmacological Society.

Entities:  

Keywords:  diabetes; inflammation; ischaemia; protease; renal failure; sepsis

Mesh:

Substances:

Year:  2015        PMID: 25778676      PMCID: PMC4574825          DOI: 10.1111/bcp.12629

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  153 in total

Review 1.  Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability.

Authors:  Andrew H J Salmon; Simon C Satchell
Journal:  J Pathol       Date:  2012-03       Impact factor: 7.996

2.  Contrasting effects of colloid and crystalloid resuscitation fluids on cardiac vascular permeability.

Authors:  Matthias Jacob; Dirk Bruegger; Markus Rehm; Ulrich Welsch; Peter Conzen; Bernhard F Becker
Journal:  Anesthesiology       Date:  2006-06       Impact factor: 7.892

3.  Physiological levels of A-, B- and C-type natriuretic peptide shed the endothelial glycocalyx and enhance vascular permeability.

Authors:  Matthias Jacob; Thomas Saller; Daniel Chappell; Markus Rehm; Ulrich Welsch; Bernhard F Becker
Journal:  Basic Res Cardiol       Date:  2013-04-06       Impact factor: 17.165

4.  Acute cardiac inflammatory responses to postischemic reperfusion during cardiopulmonary bypass.

Authors:  S Zahler; P Massoudy; H Hartl; C Hähnel; H Meisner; B F Becker
Journal:  Cardiovasc Res       Date:  1999-03       Impact factor: 10.787

5.  Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice.

Authors:  C M Alexander; F Reichsman; M T Hinkes; J Lincecum; K A Becker; S Cumberledge; M Bernfield
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

6.  Increased plasma hyaluronan in severe pre-eclampsia and eclampsia.

Authors:  S Berg; A Engman; S Holmgren; T Lundahl; T C Laurent
Journal:  Scand J Clin Lab Invest       Date:  2001-04       Impact factor: 1.713

7.  Glycocalyx protection reduces leukocyte adhesion after ischemia/reperfusion.

Authors:  Daniel Chappell; Nina Dörfler; Matthias Jacob; Markus Rehm; Ulrich Welsch; Peter Conzen; Bernhard F Becker
Journal:  Shock       Date:  2010-08       Impact factor: 3.454

8.  Evaluation of the association of serum levels of hyaluronic acid, sICAM-1, sVCAM-1, and VEGF-A with mortality and prognosis in patients with Crimean-Congo hemorrhagic fever.

Authors:  Baris Ozturk; Ferit Kuscu; Ediz Tutuncu; Irfan Sencan; Yunus Gurbuz; Hakan Tuzun
Journal:  J Clin Virol       Date:  2009-12-11       Impact factor: 3.168

Review 9.  Towards the physiological function of uric acid.

Authors:  B F Becker
Journal:  Free Radic Biol Med       Date:  1993-06       Impact factor: 7.376

Review 10.  Syndecans as modulators and potential pharmacological targets in cancer progression.

Authors:  Despoina Barbouri; Nikolaos Afratis; Chrisostomi Gialeli; Demitrios H Vynios; Achilleas D Theocharis; Nikos K Karamanos
Journal:  Front Oncol       Date:  2014-02-03       Impact factor: 6.244

View more
  127 in total

1.  Correlation Between Wall Shear Stress and Acute Degradation of the Endothelial Glycocalyx During Cardiopulmonary Bypass.

Authors:  Guoliang He; Yuan Gao; Linya Feng; Guodong He; Qiaolin Wu; Wei Gao; Lina Lin; Weijian Wang
Journal:  J Cardiovasc Transl Res       Date:  2020-06-03       Impact factor: 4.132

2.  Effect of diabetes and hyaluronidase on the retinal endothelial glycocalyx in mice.

Authors:  Wendy Leskova; Haley Pickett; Randa S Eshaq; Bandana Shrestha; Christopher B Pattillo; Norman R Harris
Journal:  Exp Eye Res       Date:  2018-11-13       Impact factor: 3.467

3.  Inhibition of inflammation induced shedding of the endothelial glycocalyx with low molecular weight heparin.

Authors:  Herbert H Lipowsky; Anne Lescanic
Journal:  Microvasc Res       Date:  2017-03-27       Impact factor: 3.514

4.  Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia.

Authors:  Vincent Hayes; Ian Johnston; Gowthami M Arepally; Steven E McKenzie; Douglas B Cines; Lubica Rauova; Mortimer Poncz
Journal:  J Clin Invest       Date:  2017-02-20       Impact factor: 14.808

5.  Biomarkers of Glycocalyx Injury are Associated with Delayed Cerebral Ischemia Following Aneurysmal Subarachnoid Hemorrhage: A Case Series Supporting a New Hypothesis.

Authors:  Josh D Bell; Shawn G Rhind; Alex P Di Battista; R Loch Macdonald; Andrew J Baker
Journal:  Neurocrit Care       Date:  2017-06       Impact factor: 3.210

Review 6.  Endothelial Cell Metabolism.

Authors:  Guy Eelen; Pauline de Zeeuw; Lucas Treps; Ulrike Harjes; Brian W Wong; Peter Carmeliet
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

Review 7.  The Pathological Relevance of Increased Endothelial Glycocalyx Permeability.

Authors:  Matthew J Butler; Colin J Down; Rebecca R Foster; Simon C Satchell
Journal:  Am J Pathol       Date:  2020-02-06       Impact factor: 4.307

Review 8.  The multifaceted role of ischemia/reperfusion in sickle cell anemia.

Authors:  Robert P Hebbel; John D Belcher; Gregory M Vercellotti
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

9.  Blueberry metabolites restore cell surface glycosaminoglycans and attenuate endothelial inflammation in diabetic human aortic endothelial cells.

Authors:  Brett Ronald Cutler; Samira Gholami; Jie Shi Chua; Balagurunathan Kuberan; Pon Velayutham Anandh Babu
Journal:  Int J Cardiol       Date:  2018-03-08       Impact factor: 4.164

10.  Circulating Neutrophil Extracellular Traps and Neutrophil Activation Are Increased in Proportion to Disease Severity in Human Malaria.

Authors:  Steven Kho; Gabriela Minigo; Benediktus Andries; Leo Leonardo; Pak Prayoga; Jeanne R Poespoprodjo; Enny Kenangalem; Ric N Price; Tonia Woodberry; Nicholas M Anstey; Tsin W Yeo
Journal:  J Infect Dis       Date:  2019-05-24       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.